抑制剂-话题@MedSci

#抑制剂#

1990篇内容 | 3168人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1852909, encodeId=0bae185290932, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Eur J Cancer：MEK抑制剂治疗NRAS突变型转移性黑色素瘤的真实临床疗效, objectType=article, longId=300803, objectId=cb143008036b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb143008036b, replyNumber=0, likeNumber=96, createdTime=2022-12-11, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb143008036b, moduleTitle=Eur J Cancer：MEK抑制剂治疗NRAS突变型转移性黑色素瘤的真实临床疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb143008036b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852736, encodeId=51c81852e362d, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Lancet Respirat Med：长期应用ASK1抑制剂Selonsertib是否可降低PAH患者的肺血管阻力？, objectType=article, longId=216127, objectId=ab2e21612efa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ab2e21612efa, replyNumber=0, likeNumber=65, createdTime=2021-12-10, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ab2e21612efa, moduleTitle=Lancet Respirat Med：长期应用ASK1抑制剂Selonsertib是否可降低PAH患者的肺血管阻力？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ab2e21612efa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852944, encodeId=be261852944c7, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Clin Oncol：EGFR抑制剂治疗EGFR扩增的胃食管交界癌的疗效, objectType=article, longId=724167, objectId=fa55e2416717, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa55e2416717, replyNumber=0, likeNumber=72, createdTime=2022-10-20, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa55e2416717, moduleTitle=J Clin Oncol：EGFR抑制剂治疗EGFR扩增的胃食管交界癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa55e2416717)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852979, encodeId=a07018529e9f3, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Lancet rheumatology：免疫介导性炎症性疾病患者使用免疫抑制剂进行第二次和第三次SARS-CoV-2疫苗接种后的体液反应：一项队列研究, objectType=article, longId=728016, objectId=b659e280163b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b659e280163b, replyNumber=0, likeNumber=67, createdTime=2023-02-09, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b659e280163b, moduleTitle=Lancet rheumatology：免疫介导性炎症性疾病患者使用免疫抑制剂进行第二次和第三次SARS-CoV-2疫苗接种后的体液反应：一项队列研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b659e280163b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852991, encodeId=890818529912f, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=ASCO：两种检查点抑制剂组合治疗皮肤黑色素瘤的疗效——系统回顾结果, objectType=article, longId=728226, objectId=c05ae282264e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c05ae282264e, replyNumber=0, likeNumber=87, createdTime=2022-08-29, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c05ae282264e, moduleTitle=ASCO：两种检查点抑制剂组合治疗皮肤黑色素瘤的疗效——系统回顾结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c05ae282264e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852873, encodeId=2f7818528e359, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JAMA：在肝素治疗基础上添加P2Y12抑制剂对改善新冠肺炎住院患者预后无益, objectType=article, longId=294328, objectId=43cc29432875, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43cc29432875, replyNumber=0, likeNumber=71, createdTime=2022-08-25, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43cc29432875, moduleTitle=JAMA：在肝素治疗基础上添加P2Y12抑制剂对改善新冠肺炎住院患者预后无益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43cc29432875)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852851, encodeId=da021852851c8, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Immunother Cancer：中肿团队CAPTAIN研究证实国产PD-1抑制剂Camrelizumab（卡瑞利珠单抗）后线治疗复发或转移鼻咽癌疗效显著, objectType=article, longId=292765, objectId=7f53292e6591, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f53292e6591, replyNumber=0, likeNumber=75, createdTime=2022-11-12, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f53292e6591, moduleTitle=J Immunother Cancer：中肿团队CAPTAIN研究证实国产PD-1抑制剂Camrelizumab（卡瑞利珠单抗）后线治疗复发或转移鼻咽癌疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f53292e6591)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852988, encodeId=59aa185298898, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=ACS NANO：突破血脑屏障，纳米颗粒携带抑制剂激活免疫系统，智取脑肿瘤，还能防复发, objectType=article, longId=728248, objectId=4135e2824819, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4135e2824819, replyNumber=0, likeNumber=89, createdTime=2022-07-08, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4135e2824819, moduleTitle=ACS NANO：突破血脑屏障，纳米颗粒携带抑制剂激活免疫系统，智取脑肿瘤，还能防复发, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4135e2824819)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852983, encodeId=0fc618529831a, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Dermatol Ther：一线治疗Hedgehog抑制剂停药后基底细胞癌患者的治疗模式和预后, objectType=article, longId=727196, objectId=5f66e27196e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5f66e27196e1, replyNumber=0, likeNumber=101, createdTime=2023-05-02, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5f66e27196e1, moduleTitle=Dermatol Ther：一线治疗Hedgehog抑制剂停药后基底细胞癌患者的治疗模式和预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5f66e27196e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852855, encodeId=3eef1852855d2, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Am Acad Dermatol ：组织蛋白酶S抑制剂对中、重度银屑病患者疗效和安全性的研究, objectType=article, longId=293131, objectId=686729313109, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=686729313109, replyNumber=0, likeNumber=66, createdTime=2022-02-05, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=686729313109, moduleTitle=J Am Acad Dermatol ：组织蛋白酶S抑制剂对中、重度银屑病患者疗效和安全性的研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=686729313109)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852725, encodeId=dcdc1852e25c0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=JNCCN:黑色素瘤患者出现肾上腺转移则对免疫检查点抑制剂耐药, objectType=article, longId=215390, objectId=5ac7215390be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ac7215390be, replyNumber=0, likeNumber=79, createdTime=2022-06-04, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ac7215390be, moduleTitle=JNCCN:黑色素瘤患者出现肾上腺转移则对免疫检查点抑制剂耐药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ac7215390be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852896, encodeId=8a5518528966e, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Clin Cancer Res：地西他滨联合PARP抑制剂他唑帕尼治疗难治性/复发性急性髓性白血病, objectType=article, longId=299624, objectId=273529962455, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=273529962455, replyNumber=0, likeNumber=73, createdTime=2022-12-09, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=273529962455, moduleTitle=Clin Cancer Res：地西他滨联合PARP抑制剂他唑帕尼治疗难治性/复发性急性髓性白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=273529962455)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852995, encodeId=5e681852995f2, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=NEJM：PDE4B抑制剂BI 1015550 可防止特发性肺纤维化患者肺功能下降, objectType=article, longId=729469, objectId=829ae294692a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=829ae294692a, replyNumber=0, likeNumber=79, createdTime=2023-03-07, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=829ae294692a, moduleTitle=NEJM：PDE4B抑制剂BI 1015550 可防止特发性肺纤维化患者肺功能下降, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=829ae294692a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852966, encodeId=77311852966c9, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=众生药业抗新型冠状病毒3CL蛋白酶抑制剂一类创新药物RAY1216片获准IND, objectType=article, longId=727033, objectId=76d9e2703326, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76d9e2703326, replyNumber=0, likeNumber=88, createdTime=2022-06-15, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76d9e2703326, moduleTitle=众生药业抗新型冠状病毒3CL蛋白酶抑制剂一类创新药物RAY1216片获准IND, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76d9e2703326)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853001, encodeId=a7aa185300123, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Diabetes Obes Metab：二肽基肽酶-4抑制剂利格列汀与磺脲类格列美脲在成人2型糖尿病患者餐后肾血流动力学影响, objectType=article, longId=219911, objectId=452e2199110c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=452e2199110c, replyNumber=0, likeNumber=67, createdTime=2022-07-28, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=452e2199110c, moduleTitle=Diabetes Obes Metab：二肽基肽酶-4抑制剂利格列汀与磺脲类格列美脲在成人2型糖尿病患者餐后肾血流动力学影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=452e2199110c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852771, encodeId=62dc1852e71fb, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=除了症状表现之外，是否有检验指标可以准确判断免疫抑制剂该不该停用?, objectType=article, longId=218310, objectId=0b6c21831018, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b6c21831018, replyNumber=0, likeNumber=91, createdTime=2022-09-09, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b6c21831018, moduleTitle=除了症状表现之外，是否有检验指标可以准确判断免疫抑制剂该不该停用?, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b6c21831018)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1853008, encodeId=89af185300826, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=ARD：选择性TYK2抑制剂德卡伐替尼在银屑病关节炎II期试验中的疗效和安全性, objectType=article, longId=730645, objectId=8303e3064580, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8303e3064580, replyNumber=0, likeNumber=119, createdTime=2023-05-05, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8303e3064580, moduleTitle=ARD：选择性TYK2抑制剂德卡伐替尼在银屑病关节炎II期试验中的疗效和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8303e3064580)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852948, encodeId=026e185294895, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=J Clin Rheumatol：类风湿性关节炎患者使用JAK抑制剂感染风险是否会增加？, objectType=article, longId=724209, objectId=2b6fe24209ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2b6fe24209ff, replyNumber=0, likeNumber=78, createdTime=2023-01-31, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b6fe24209ff, moduleTitle=J Clin Rheumatol：类风湿性关节炎患者使用JAK抑制剂感染风险是否会增加？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b6fe24209ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852717, encodeId=36c91852e17b0, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Diabetes Care：2型糖尿病患者SGLT2抑制剂与视网膜静脉阻塞风险的关系, objectType=article, longId=214922, objectId=a0cf214922cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0cf214922cb, replyNumber=0, likeNumber=78, createdTime=2022-05-11, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0cf214922cb, moduleTitle=Diabetes Care：2型糖尿病患者SGLT2抑制剂与视网膜静脉阻塞风险的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0cf214922cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1852774, encodeId=2c161852e7412, content=<a href='/topic/show?id=f0a254918f0' target=_blank style='color:#2F92EE;'>#抑制剂#</a>, objectTitle=Front Oncol：安罗替尼联合PD-1抑制剂治疗晚期实体肿瘤有效且毒性可控, objectType=article, longId=218379, objectId=64ef2183e9b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64ef2183e9b4, replyNumber=0, likeNumber=141, createdTime=2022-05-29, rootId=0, userName=jklm09, userId=44a360, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64ef2183e9b4, moduleTitle=Front Oncol：安罗替尼联合PD-1抑制剂治疗晚期实体肿瘤有效且毒性可控, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64ef2183e9b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抑制剂

2020-05-29

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Eur J Cancer：MEK抑制剂治疗NRAS突变型转移性黑色素瘤的真实临床疗效

2022-12-11

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Lancet Respirat Med：长期应用ASK1抑制剂Selonsertib是否可降低PAH患者的肺血管阻力？

2021-12-10

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Clin Oncol：EGFR抑制剂治疗EGFR扩增的胃食管交界癌的疗效

2022-10-20

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Lancet rheumatology：免疫介导性炎症性疾病患者使用免疫抑制剂进行第二次和第三次SARS-CoV-2疫苗接种后的体液反应：一项队列研究

2023-02-09

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

ASCO：两种检查点抑制剂组合治疗皮肤黑色素瘤的疗效——系统回顾结果

2022-08-29

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JAMA：在肝素治疗基础上添加P2Y12抑制剂对改善新冠肺炎住院患者预后无益

2022-08-25

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Immunother Cancer：中肿团队CAPTAIN研究证实国产PD-1抑制剂Camrelizumab（卡瑞利珠单抗）后线治疗复发或转移鼻咽癌疗效显著

2022-11-12

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

ACS NANO：突破血脑屏障，纳米颗粒携带抑制剂激活免疫系统，智取脑肿瘤，还能防复发

2022-07-08

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Dermatol Ther：一线治疗Hedgehog抑制剂停药后基底细胞癌患者的治疗模式和预后

2023-05-02

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Am Acad Dermatol ：组织蛋白酶S抑制剂对中、重度银屑病患者疗效和安全性的研究

2022-02-05

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

JNCCN:黑色素瘤患者出现肾上腺转移则对免疫检查点抑制剂耐药

2022-06-04

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Clin Cancer Res：地西他滨联合PARP抑制剂他唑帕尼治疗难治性/复发性急性髓性白血病

2022-12-09

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

NEJM：PDE4B抑制剂BI 1015550 可防止特发性肺纤维化患者肺功能下降

2023-03-07

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

众生药业抗新型冠状病毒3CL蛋白酶抑制剂一类创新药物RAY1216片获准IND

2022-06-15

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Diabetes Obes Metab：二肽基肽酶-4抑制剂利格列汀与磺脲类格列美脲在成人2型糖尿病患者餐后肾血流动力学影响

2022-07-28

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

除了症状表现之外，是否有检验指标可以准确判断免疫抑制剂该不该停用?

2022-09-09

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

ARD：选择性TYK2抑制剂德卡伐替尼在银屑病关节炎II期试验中的疗效和安全性

2023-05-05

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

J Clin Rheumatol：类风湿性关节炎患者使用JAK抑制剂感染风险是否会增加？

2023-01-31

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Diabetes Care：2型糖尿病患者SGLT2抑制剂与视网膜静脉阻塞风险的关系

2022-05-11

jklm09 (审核中...)

前往app查看评论内容

#抑制剂#

Front Oncol：安罗替尼联合PD-1抑制剂治疗晚期实体肿瘤有效且毒性可控

2022-05-29

科室
- - 订阅+
  - 更多科室
工具
服务